The Life Sciences team advised Quotient Therapeutics on entering a multi-year research collaboration agreement with Merck to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient's somatic genomics platform technology. Under the terms of the agreement, Quotient will receive an upfront payment of $20 million. Quotient is also eligible to receive development, regulatory, and commercial milestones for a potential total deal value of up to $2.2 billion.
Quotient Therapeutics develops breakthrough medicines informed by natural somatic genetic diversity present in patients. Through its integrated somatic genomics and computational technologies, Quotient gains unbiased, unprecedented resolution into disease-causal drug targets that it leverages to design and develop first-in-class therapies. Quotient was founded by Flagship Pioneering in 2022.
The Goodwin team was led by Felipe M. Heiderich and Nancy Urizar and included Bill Collins, Adam Bellack, Kevin Walsh, Dan Karelitz, Susan Lee, Barry Bazian, Curtis McCluskey, and Austin Church.
For more information on the deal, please read the press release.